Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la Colesterolemia en España, 2000. Instrumento para la prevención cardiovascular.
Clin Invest Arterioscler, 12 (2000), pp. 125-152
[2.]
National Cholesterol Education Program. Second report of the expert committee on detection, evaluation, and treatment of high blood cholesterol in adults.
Circulation, 89 (1994), pp. 1333-1345
[3.]
P. Plans, J. Rovira.
Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes.
Med Clín (Barc, 105 (1995), pp. 327-333
[4.]
P. Plans-Rubió.
Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the primary prevention of coronary heart disease. Evaluative study carried out in Spain.
PharmacoEconomics, 13 (1998), pp. 623-643
[5.]
P. Plans-Rubió.
Cost-effectiveness of cardiovascular prevention programmes in Spain.
Int J Tech Assess Health Care, 14 (1998), pp. 320-330
[6.]
M.F. Drummond, B. O’Brien, G.L. Stoddart, G.W. Torrance.
Oxford University Press, (1997),
[7.]
M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein.
Oxford University Press, (1996),
[8.]
M.C. Weinstein.
Principles of cost-effectiveness resource allocation in health care organizations.
Int J Tech Assess Health Care, 6 (1990), pp. 93-103
[9.]
A. Laupacis, D. Feeny, A.S. Detsky, P.X. Tugwell.
Howattractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
Can Med Association J, 146 (1992), pp. 473-481
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.